Group 1 - The core viewpoint of the articles indicates that the Hong Kong stock market is facing challenges, particularly in terms of liquidity and performance compared to the A-share market, with a focus on value investment and risk management strategies [1][3][6] - In 2025, the Hong Kong stock market saw significant activity in sectors like innovative drugs and artificial intelligence, but by the end of the year, these sectors experienced a downturn, leading to a lack of high-performing funds in these themes [2][3] - The liquidity issues in the Hong Kong market are characterized by a concentration of trading in large-cap stocks, while small-cap stocks suffer from low trading volumes, leading to a disparity in market performance [3][4] Group 2 - Fund managers emphasize the importance of focusing on fundamental performance and quality of companies when investing in the Hong Kong market, as external factors and macroeconomic conditions heavily influence market dynamics [5][6] - The outlook for the Hong Kong market suggests that sectors such as technology and consumer goods may become key investment themes, with a belief that the market's valuation remains attractive compared to global peers [7][8] - There is a growing interest in high-quality consumer brands and innovative companies within the tea beverage sector, which are expected to achieve stable long-term growth due to their competitive advantages [8]

Group 1 - The core investment logic for public funds in Hong Kong stocks is shifting from chasing market hotspots to deeply exploring internal alpha opportunities within industries as the era of "beta" gains from popular sectors comes to an end [1][2] - The valuation repair of Hong Kong stocks is nearly complete, making it difficult to rely solely on index strategies or betting on hot sectors for sustained success [1][2] - The investment perspective is transitioning from emotion-driven narratives to profit-driven fundamental verification, with a focus on "distilling the truth" becoming key to evaluating research and investment capabilities [1][2] Group 2 - The performance of public funds in Hong Kong stocks is increasingly seen as a test of fund managers' true stock-picking abilities, with the ability to identify companies with sustainable growth and explosive performance becoming crucial [2][4] - The consensus among public funds is that the previous beta-driven market rally is over, and the focus will shift to companies with tangible performance rather than those relying on storytelling [3][4] - Fund managers emphasize the importance of actual performance metrics, such as operating cash flow and successful overseas business development (BD) transactions, as indicators of a company's viability [6][7] Group 3 - The investment strategy is evolving towards a balanced approach, combining growth-oriented investments with high-dividend defensive positions to achieve risk and return balance [8][9] - There is a growing interest in sectors that are currently at the bottom of the cycle, such as consumer stocks, which are seen as having potential for recovery and attractive valuations [8][9] - The focus for 2026 will be on two main areas: AI applications and non-AI growth sectors, as well as the real estate chain, which may present unique investment opportunities [9]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of January 11, 2026 [3] Core Insights - 2025 marked a significant year for Chinese innovative drugs going overseas, with total transaction amounts reaching $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs [4] - The innovative drug index saw a 35.31% increase in 2025, outperforming the CSI 300 index by 17.65% [4] - The trend of Chinese innovative drugs going global is expected to strengthen in 2026, with significant deals such as the one between Yilian Biotech and Roche for the YL201 project, which includes a $570 million upfront payment [4] - The small nucleic acid drug sector is experiencing breakthroughs, with GSK's Bepirovirsen showing positive results in Phase III trials for chronic hepatitis B, potentially becoming the first drug to achieve functional cure [5] - The report highlights the importance of oral autoimmune drugs, with Takeda's TYK2 inhibitor showing promising results in treating moderate to severe plaque psoriasis [6] - The brain-computer interface technology is entering a critical industrialization phase, with companies like Neuralink set to produce devices in 2026, supported by favorable policies and clinical trials in China [8] - The ZAP-X radiotherapy device is expected to capture a significant market opportunity in China, with the non-invasive tumor radiotherapy market projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024 [10] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 2.13% over the past week, ranking 25th among 31 industry indices [28] - Over the past month, the pharmaceutical industry index also lagged behind the CSI 300 by 5.42%, ranking 27th [29] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 36.95, above the five-year historical average of 31.12 [52] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral drugs, and the impact of policy support on the inhalation drug industry [55] 4. Important Industry Policies and News - Recent policies include the issuance of the fourth batch of encouraged generic drug directories by the National Medical Products Administration [57] - Significant news includes GSK's announcement of positive Phase III results for Bepirovirsen and Yilian Biotech's licensing agreement with Roche [58][59]

Core Insights - The report continues to recommend innovative drugs and the related industry chain, highlighting the strong growth potential in the pharmaceutical sector through 2026 [1][4]. Investment Strategy - The investment strategy emphasizes the focus on the CXO sector, particularly in chemical CDMO, where Chinese companies hold significant advantages in talent, chemical capabilities, compliance production, and intellectual property protection [4]. - The report suggests that the upcoming JPM conference will provide updates on the operational progress of Chinese innovative drug companies, which have shown a long-term positive development trend [4]. - The recommended investment portfolio includes A-shares such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, as well as H-shares like Kangfang Biologics and WuXi Biologics [4][5]. Industry Performance - The pharmaceutical industry experienced a decline of 4.10% in December, underperforming the CSI 300 index by 6.38% [8]. - The report notes that the chemical pharmaceutical sector saw the largest declines among sub-sectors, with a drop of 5.80% [12]. Market Data - For the period from January to November 2025, the pharmaceutical manufacturing industry's total revenue was 220.65 billion yuan, reflecting a year-on-year decrease of 2.0% [7]. - The total retail sales of consumer goods reached 45.61 trillion yuan, with retail sales of Western and Chinese medicines amounting to 660.4 billion yuan, a year-on-year increase of 1.8% [7]. Regulatory Environment - The report discusses the impact of the U.S. "Biological Safety Act," which is expected to have a limited short-term effect on Chinese CXO companies, while emphasizing the need to monitor the long-term implications of international competition and regulatory changes [22]. Recent Drug Approvals - In December 2025, a total of 16 innovative drugs or biosimilars were approved for market entry, including six domestic and ten imported products [24][25].

Quantitative Models and Construction Methods 1. Model Name: DTW Timing Model - **Model Construction Idea**: The DTW timing model is based on a similarity approach, analyzing the similarity between current index trends and historical trends. It selects historical segments with high similarity as references and calculates the weighted average future returns and standard deviations of these segments to generate trading signals [20][22]. - **Model Construction Process**: 1. Use the DTW (Dynamic Time Warping) distance algorithm instead of Euclidean distance to measure similarity, as DTW is better suited for time series problems by addressing sequence misalignment issues [22]. 2. Calculate the weighted average future returns and standard deviations of selected historical segments, where weights are the inverse of the DTW distance [20]. 3. Generate trading signals based on the average future returns and standard deviations [20]. 4. To address the "pathological matching" issue in traditional DTW algorithms, improved DTW algorithms with boundary constraints (e.g., Sakoe-Chiba and Itakura Parallelogram) are applied [24][26][28]. - **Model Evaluation**: The DTW timing model demonstrates stable excess returns in general market conditions but may underperform during periods of sudden macroeconomic policy changes [9]. 2. Model Name: Foreign Capital Timing Model - **Model Construction Idea**: This model leverages information embedded in the price movements of two offshore assets related to A-shares: FTSE China A50 Index Futures (Singapore market) and the Southbound A50 ETF (Hong Kong market) [30]. - **Model Construction Process**: 1. Construct two indicators using FTSE China A50 Index Futures: basis and price divergence [30]. 2. Construct a price divergence indicator using the Southbound A50 ETF [30]. 3. Combine the timing signals from the two assets to form the foreign capital timing signal [30]. - **Model Evaluation**: The model achieves strong performance, with annualized returns of 18.96% (long-short strategy) and 14.19% (long-only strategy) over the full sample period (2014-2024). It also exhibits a high win rate (close to 55%) and a profit-loss ratio exceeding 2.5 [13]. --- Model Backtesting Results 1. DTW Timing Model - **Absolute Return**: 35.52% since November 2022 [9] - **Excess Return (relative to CSI 300)**: 8.60% [9] - **Maximum Drawdown**: 21.32% [9] 2. Foreign Capital Timing Model - **Annualized Return (Long-Short Strategy)**: 18.96% (2014-2024) [13] - **Annualized Return (Long-Only Strategy)**: 14.19% (2014-2024) [13] - **Maximum Drawdown**: 25.69% (Long-Short), 17.27% (Long-Only) [13] - **Win Rate**: Close to 55% [13] - **Profit-Loss Ratio**: Exceeds 2.5 [13] - **Absolute Return (2024)**: 31.33% (Long-Only Strategy) [17] - **Maximum Drawdown (2024)**: 8.23% [17] --- Quantitative Factors and Construction Methods 1. Factor Name: DTW Distance - **Factor Construction Idea**: DTW distance is used as a similarity measure for time series, addressing sequence misalignment issues that arise with traditional Euclidean distance [22]. - **Factor Construction Process**: 1. Compute the DTW distance between the current index trend and historical trends [22]. 2. Use the inverse of the DTW distance as weights to calculate the weighted average future returns and standard deviations of historical segments [20]. 3. Generate trading signals based on these weighted averages [20]. - **Factor Evaluation**: DTW distance is more effective for time series problems compared to Euclidean distance, as it resolves sequence misalignment and improves model performance [22]. 2. Factor Name: Basis and Price Divergence (Foreign Capital Timing Model) - **Factor Construction Idea**: These factors are derived from offshore assets to capture information about A-share market trends [30]. - **Factor Construction Process**: 1. Calculate the basis and price divergence indicators using FTSE China A50 Index Futures [30]. 2. Calculate the price divergence indicator using the Southbound A50 ETF [30]. 3. Combine these indicators to form the foreign capital timing signal [30]. - **Factor Evaluation**: These factors effectively capture offshore market signals and contribute to the strong performance of the foreign capital timing model [13]. --- Factor Backtesting Results 1. DTW Distance - **Absolute Return**: 35.52% since November 2022 [9] - **Excess Return (relative to CSI 300)**: 8.60% [9] - **Maximum Drawdown**: 21.32% [9] 2. Basis and Price Divergence - **Annualized Return (Long-Short Strategy)**: 18.96% (2014-2024) [13] - **Annualized Return (Long-Only Strategy)**: 14.19% (2014-2024) [13] - **Maximum Drawdown**: 25.69% (Long-Short), 17.27% (Long-Only) [13] - **Win Rate**: Close to 55% [13] - **Profit-Loss Ratio**: Exceeds 2.5 [13] - **Absolute Return (2024)**: 31.33% (Long-Only Strategy) [17] - **Maximum Drawdown (2024)**: 8.23% [17]

Core Insights - The price of experimental monkeys, particularly the crab-eating macaque, has surged dramatically, reaching prices between 120,000 to 150,000 yuan, marking a 30% increase over the past two months and nearing historical peaks [1][2] - The supply-demand imbalance in the experimental monkey market is expected to persist due to long breeding cycles and a significant aging population of breeding monkeys, leading to a projected annual shortfall of approximately 10,000 monkeys from 2025 to 2027 [2][3] - The demand for experimental monkeys is closely tied to the recovery of the innovative drug industry, driven by an increase in overseas licensing deals and a growing need for research related to aging populations and chronic diseases [3][4] Supply and Demand Dynamics - The breeding cycle for experimental monkeys is lengthy, requiring around 6-7 years before they can be used in research, which limits the ability to quickly scale supply [2] - A significant portion of the breeding population is aging, with only 40% survival rates for breeding mothers, exacerbating the supply issues [2] - The demand for experimental monkeys is projected to reach between 51,300 to 62,600 annually, while supply is only expected to be between 49,000 to 52,400, indicating a growing gap [2] Market Response and Investment Opportunities - The capital market has reacted positively, with innovative drug-related sectors seeing over a 50% increase in stock prices, significantly outperforming the broader market [4] - The net profit of the pharmaceutical R&D outsourcing sector has increased by 56.96% year-on-year, indicating strong performance driven by rising research demands [4] - Companies that have secured monkey resources through acquisitions are positioned to withstand cost fluctuations and maintain research progress, making them attractive investment opportunities [6] Risks and Challenges - There is a notable internal differentiation within the pharmaceutical sector, with many companies facing revenue declines due to slow R&D progress and commercialization challenges [5] - Rising costs associated with the increased price of experimental monkeys may hinder the progress of smaller companies, potentially leading to pipeline stagnation [5] - Ongoing policy pressures and competition in the market may further complicate the landscape for innovative drug development [5]

Core Viewpoint - The logic of industry-themed funds is changing, moving away from a passive "beta" strategy focused on popular sectors, and towards a more active search for "alpha" opportunities within industries as public funds increasingly focus on performance-driven investments by 2026 [1][2]. Group 1: Market Dynamics - The simple strategy of investing in popular sectors for easy gains has ended, with a shift towards showcasing fund managers' stock-picking abilities in an "alpha" market [2]. - The 2025 annual ranking of Hong Kong QDII funds showed that industry allocation was key to the top-performing funds, indicating a transition to a more competitive investment landscape [2]. - The influx of southbound capital into Hong Kong stocks in 2025 has started to influence pricing in popular sectors, but the market is expected to balance between southbound and foreign capital in 2026 [3]. Group 2: Investment Strategy - Fund managers are now less willing to invest based on "stories" and are demanding tangible performance metrics, indicating a shift towards profitability-driven investments [4]. - The 2026 investment landscape will likely see reduced opportunities for broad-based gains across sectors, with a greater emphasis on individual company performance [4]. - The focus will be on companies that can demonstrate real financial performance rather than those that rely solely on narrative-driven growth [6]. Group 3: Sector-Specific Insights - The importance of overseas business development (BD) deals is highlighted, as they serve as a credibility endorsement for domestic innovative drug companies, impacting their valuation [7]. - In the AI sector, while hardware remains a strong investment, concerns about the application side's profitability are emerging, suggesting a need for careful evaluation of cash flow sources [7]. - The investment strategy for 2026 will emphasize a balanced approach, combining growth-oriented investments with high-dividend stocks to manage risk and return effectively [8]. Group 4: Future Outlook - The market is expected to transition from extreme growth to a more balanced strategy, with a focus on sectors that are currently undervalued and have potential for recovery [8]. - Fund managers are advised to explore non-consensus opportunities, particularly in consumer sectors that are at historical low levels of market expectations and institutional holdings [8].

Market Review - The CITIC Medical Index increased by 7.70%, outperforming the CSI 300 Index by 4.91 percentage points, ranking 5th among 30 primary industries [8] - The top ten stocks by increase this week include: Bibet-U, Innovation Medical, Sanbo Brain Science, and others, with significant gains [8] - The top ten stocks by decrease include: Baihua Medicine, Jinhao Medical, and others, with notable declines [8] Overall View and Investment Themes - The domestic innovative drug industry is transitioning from quantity logic to quality logic, focusing on differentiated and internationalized pipelines, with an emphasis on products that can generate profits by 2025 [11] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, with ongoing updates and acceleration in overseas expansion [11] - The innovative chain (CXO + life science services) is expected to see a rebound in overseas investment, with domestic investment stabilizing, indicating a potential bottoming out [11] - The pharmaceutical industry is anticipated to enter a new growth cycle, with cost improvements in specialty raw materials and a focus on patent expirations leading to new growth opportunities [11] Traditional Chinese Medicine - The basic drug directory is expected to be released, with unique basic drugs projected to grow faster than non-basic drugs, indicating a potential market rebound [12] - The reform of state-owned enterprises is expected to enhance the fundamental performance of companies, particularly after adjustments to the evaluation system [12] - The new medical insurance directory is expected to benefit certain companies, with a focus on OTC enterprises that cater to aging populations and have strong dividend characteristics [12] Medical Services - The anti-corruption and centralized procurement efforts are expected to purify the medical market environment, enhancing the competitiveness of private medical services [12] - The rapid expansion of commercial insurance and self-funded medical services is likely to provide more competitive advantages for private healthcare providers [12] Blood Products - The approval of plasma stations is expected to increase supply, with companies expanding their product offerings and production capacity, indicating a clear long-term growth path for the blood products industry [12]

- The report does not contain any quantitative models or factors for analysis[1][2][3]